A perfectly engineered instrument is only one part of the solution.
To support the accelerated pace of drug discovery and development, we are continuously looking for ways to improve our customers’ R&D processes.
To complement the existing sophisticated data evaluation and reporting tools in our software, we seek to align ourselves with standard platforms.
Integrating our technologies through Ready-to-Run benefits both our large and mid-sized customers.
Giving our joint customers a standard integration between Bruker instruments and the Genedata Biopharma Platform eliminates time-consuming integrations and customizations.
The instrument must be effectively integrated to visualize, analyze and manage data in the same workflow.
Ready-to-Run enables easy data sharing and improved visibility into data, which makes it ideal for large organizations where research functions are geographically dispersed.
Our customers benefit from a new level of automation and streamlined workflows, which increases the speed of data analysis while improving overall results quality and R&D efficiency.
Mid-sized companies benefit from the capability to analyze screening data from many different sources related by compound or biology.
Through the Ready-to-Run program we are empowering our customers to achieve a new level of screening data management.
The Ready-to-Run program streamlines the screening workflow for customers and enables them to analyze and view the results of large screening data sets within one software—all of which drives more rapid and informed decision making.